The current stock price of SNCE is 5.75 USD. In the past month the price increased by 1.23%. In the past year, price decreased by -19.47%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.85 | 217.58B | ||
| DHR | DANAHER CORP | 30.02 | 163.50B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 185.88 | 56.48B | ||
| A | AGILENT TECHNOLOGIES INC | 24.79 | 39.21B | ||
| IQV | IQVIA HOLDINGS INC | 19.43 | 38.49B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.87 | 28.95B | ||
| WAT | WATERS CORP | 30.3 | 22.91B | ||
| ILMN | ILLUMINA INC | 31.04 | 20.68B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.13 | 19.90B | ||
| MEDP | MEDPACE HOLDINGS INC | 39.99 | 16.11B | ||
| TEM | TEMPUS AI INC | N/A | 11.43B | ||
| RVTY | REVVITY INC | 20.2 | 10.97B |
Science 37 Holdings Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Research Triangle Park, North Carolina and currently employs 460 full-time employees. The company went IPO on 2020-11-20. Science 37 Holdings, Inc. is engaged in patient-centric clinical trials and in supporting novel approaches to decentralized clinical trial designs. Through its patient-centric approach, it reduces the impact of the geographic barriers associated with conventional physical clinical trial sites, enabling recruitment of virtually any patient. Its offerings lie in its configurable unified technology platform combined with its centralized patient recruitment capabilities and specialized network of patient communities. Its unified technology platform is purpose-built for patient-centric clinical trial execution and is designed to provide an end-to-end, single stop solution. The company also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, and remote coordinators designed for the purpose of orchestrating patient-centric clinical trials. The company uses diversified, multi-channel programs to identify patients who fit the profile for each of its projects.
SCIENCE 37 HOLDINGS INC
800 Park Offices Drive, Suite 3606
RESEARCH TRIANGLE PARK NORTH CAROLINA US
CEO: Andrew McDonald
Employees: 460
Phone: 19843773737
Science 37 Holdings Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Research Triangle Park, North Carolina and currently employs 460 full-time employees. The company went IPO on 2020-11-20. Science 37 Holdings, Inc. is engaged in patient-centric clinical trials and in supporting novel approaches to decentralized clinical trial designs. Through its patient-centric approach, it reduces the impact of the geographic barriers associated with conventional physical clinical trial sites, enabling recruitment of virtually any patient. Its offerings lie in its configurable unified technology platform combined with its centralized patient recruitment capabilities and specialized network of patient communities. Its unified technology platform is purpose-built for patient-centric clinical trial execution and is designed to provide an end-to-end, single stop solution. The company also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, and remote coordinators designed for the purpose of orchestrating patient-centric clinical trials. The company uses diversified, multi-channel programs to identify patients who fit the profile for each of its projects.
The current stock price of SNCE is 5.75 USD. The price increased by 0.35% in the last trading session.
SNCE does not pay a dividend.
SNCE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
SNCE stock is listed on the Nasdaq exchange.
SCIENCE 37 HOLDINGS INC (SNCE) has a market capitalization of 34.67M USD. This makes SNCE a Nano Cap stock.
ChartMill assigns a technical rating of 4 / 10 to SNCE. When comparing the yearly performance of all stocks, SNCE is a bad performer in the overall market: 70.82% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to SNCE. SNCE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months SNCE reported a non-GAAP Earnings per Share(EPS) of -7.26. The EPS decreased by -881.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -164.66% | ||
| ROE | -241.1% | ||
| Debt/Equity | 0 |
10 analysts have analysed SNCE and the average price target is 14.11 USD. This implies a price increase of 145.39% is expected in the next year compared to the current price of 5.75.
For the next year, analysts expect an EPS growth of -72.66% and a revenue growth -14.69% for SNCE